BioLife Solutions
BLFS Β· Health Care Supplies
β
οΏ½οΏ½Lantheus
LNTH Β· Health Care Supplies
$99.80
0.3%The short version
- Lantheus is the larger business, with $1.5B of revenue in fiscal 2025 against $96.2M for BioLife Solutions, about 16 times as much.
- BioLife Solutions grew revenue faster (28.9%, against 0.5%).
- Lantheus kept more of each dollar of sales as operating profit (20.2% operating margin, against β17.3% operating margin).
- Lantheus turned more of its sales into free cash flow (23.0% FCF margin, against 11.1% FCF margin).
- Lantheus earned a higher return on the capital invested in it (22.7%, against β4.8%).
| Latest fiscal year | BLFS Β· FY25 | LNTH Β· FY25 |
|---|---|---|
| Size | ||
| Market cap | β | $6.7B |
| Revenue | $96.2M | $1.5B |
| Free cash flow | $10.6M | $354M |
| Net income | β$4.6M | $234M |
| Growth | ||
| Revenue growth | 28.9% | 0.5% |
| 5-year growth | 14.9% | 35.4% |
| Share count change | 5.6% | β4.5% |
| Profitability | ||
| Gross margin | 64.6% | 61.1% |
| Operating margin | β17.3% | 20.2% |
| Net margin | β4.8% | 15.2% |
| FCF margin | 11.1% | 23.0% |
| Return on capital | β4.8% | 22.7% |
| Return on equity | β1.3% | 21.5% |
| Balance sheet | ||
| Net debt | β$83.9M | $210M |
| Net debt / EBITDA | β | 0.6x |
| Dividends and buybacks | $0.0M | $300M |
| Valuation & quality | ||
| P/E | β | 24.2x |
| Piotroski F-score | 6 | 5 |
FY16
BLFS $8.2M
LNTH $302M
FY17
BLFS $11.0M
LNTH $331M
FY18
BLFS $19.7M
LNTH $343M
FY19
BLFS $27.4M
LNTH $347M
FY20
BLFS $48.1M
LNTH $339M
FY21
BLFS $119M
LNTH $425M
FY22
BLFS $76.2M
LNTH $935M
FY23
BLFS $68.0M
LNTH $1.3B
FY24
BLFS $74.6M
LNTH $1.5B
FY25
BLFS $96.2M
LNTH $1.5B
BLFS
LNTH
FY16
BLFS β59.0%
LNTH 18.8%
FY17
BLFS β9.6%
LNTH 15.7%
FY18
BLFS 18.6%
LNTH 18.8%
FY19
BLFS β0.8%
LNTH 14.9%
FY20
BLFS β13.0%
LNTH β1.2%
FY21
BLFS β29.5%
LNTH β14.3%
FY22
BLFS β7.8%
LNTH 3.9%
FY23
BLFS β25.3%
LNTH 28.1%
FY24
BLFS β6.0%
LNTH 29.8%
FY25
BLFS β17.3%
LNTH 20.2%
BLFS
LNTH
FY16
BLFS β$4.5M
LNTH $42.2M
FY17
BLFS $0.5M
LNTH $37.2M
FY18
BLFS $1.9M
LNTH $41.1M
FY19
BLFS $0.5M
LNTH $58.3M
FY20
BLFS $4.7M
LNTH $16.4M
FY21
BLFS β$13.0M
LNTH $53.9M
FY22
BLFS β$18.9M
LNTH $21.8M
FY23
BLFS β$18.9M
LNTH $260M
FY24
BLFS $5.2M
LNTH $493M
FY25
BLFS $10.6M
LNTH $354M
BLFS
LNTH
FY16
BLFS β
LNTH 41.2%
FY17
BLFS β
LNTH 30.9%
FY18
BLFS β
LNTH 24.0%
FY19
BLFS β
LNTH 23.5%
FY20
BLFS β6.5%
LNTH β0.8%
FY21
BLFS β10.5%
LNTH β8.0%
FY22
BLFS β1.3%
LNTH 6.4%
FY23
BLFS β4.2%
LNTH 46.2%
FY24
BLFS β1.2%
LNTH 47.1%
FY25
BLFS β4.8%
LNTH 22.7%
BLFS
LNTH
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.